Proactive Therapeutic Drug Monitoring of Infliximab: A Comparative Study of a New Point-of-Care Quantitative Test with Two Established ELISA Assays

BÜHLMANN Quantum Blue® Infliximab Trough Level Assay Citation:

Afonso J, Lopes S et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther. 2016 Oct;44(7):684-92. doi: 10.1111/apt.13757. Epub 2016 Aug 10. PMID: 27507790

First Publication using our Quantum Blue® Infliximab Trough Level Assay

We are very pleased to announce the publication of the first article describing our Quantum Blue® Infliximab trough level assay. The first publication of our Quantum Blue® Infliximab rapid test by Afonso et al. demonstrating the excellent correlation of the rapid test with established ELISA assays. The Quantum Blue® Infliximab rapid test offers a result within 15 minutes.

Highlight from this Publication

On the basis of this study, we may conclude that the point-of-care Quantum Blue is a reliable alternative to the time-consuming ELISAs, allowing the fast and accurate assessment of IFX levels, which in turn contributes towards a proactive and cost-effective therapeutic managing of IBD patients.”

BÜHLMANN Infliximab Trough Level ELISA is for Research Use Only in the US.
Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInEmail this to someone